JASVINDER SINGH to Rheumatic Diseases
This is a "connection" page, showing publications JASVINDER SINGH has written about Rheumatic Diseases.
Connection Strength
7.538
-
The Emerging Safety Profile of JAK Inhibitors in Rheumatic Diseases. BioDrugs. 2023 Sep; 37(5):625-635.
Score: 0.825
-
Management of Rheumatic Diseases During the COVID-19 Pandemic: A National Veterans Affairs Survey of Rheumatologists. Arthritis Care Res (Hoboken). 2021 07; 73(7):998-1003.
Score: 0.720
-
Are the days of missed or delayed diagnosis of gout over? Nat Rev Rheumatol. 2019 10; 15(10):578-580.
Score: 0.637
-
The OMERACT First-time Participant Program: Fresh Eye from the New Guys. J Rheumatol. 2017 Oct; 44(10):1560-1563.
Score: 0.540
-
OMERACT 11: international consensus conference on outcome measures in rheumatology. J Rheumatol. 2014 Jan; 41(1):145-9.
Score: 0.428
-
Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature. Immunotherapy. 2013 Mar; 5(3):265-99.
Score: 0.404
-
Effect of comorbidity on quality of life of male veterans with prevalent primary total knee arthroplasty. Clin Rheumatol. 2009 Sep; 28(9):1083-9.
Score: 0.311
-
Contributions of OMERACT to rheumatic disease research. Arthritis Rheum. 2007 Feb 15; 57(1):186.
Score: 0.266
-
Development of classification and response criteria for rheumatic diseases. Arthritis Rheum. 2006 Jun 15; 55(3):348-52.
Score: 0.254
-
OMERACT Core outcome measurement set for shared decision making in rheumatic and musculoskeletal conditions: a scoping review to identify candidate instruments. Semin Arthritis Rheum. 2024 Apr; 65:152344.
Score: 0.213
-
Telemedicine in rheumatology care: A systematic review. Semin Arthritis Rheum. 2022 10; 56:152045.
Score: 0.192
-
Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open. 2021 09; 7(3).
Score: 0.182
-
OMERACT 2020: A virtual (R)evolution. Semin Arthritis Rheum. 2021 06; 51(3):588-592.
Score: 0.177
-
Scope of Outcomes in Trials and Observational Studies of Interventions Targeting Medication Adherence in Rheumatic Conditions: A Systematic Review. J Rheumatol. 2020 10 01; 47(10):1565-1574.
Score: 0.162
-
Pain Measurement in Rheumatic and Musculoskeletal Diseases: Where To Go from Here? Report from a Special Interest Group at OMERACT 2018. J Rheumatol. 2019 10; 46(10):1355-1359.
Score: 0.154
-
OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies. J Rheumatol. 2019 08; 46(8):1021-1027.
Score: 0.153
-
OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions. J Rheumatol. 2019 10; 46(10):1409-1414.
Score: 0.152
-
Addressing Challenges in Developing a Core Domain Set in Adherence Interventions in Rheumatology: A Report from the OMERACT-Adherence Group. J Rheumatol. 2019 09; 46(9):1202-1206.
Score: 0.152
-
Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative. J Rheumatol. 2019 09; 46(9):1159-1163.
Score: 0.152
-
Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials. J Rheumatol. 2019 08; 46(8):1053-1058.
Score: 0.152
-
Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol. Trials. 2018 Mar 27; 19(1):204.
Score: 0.143
-
Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets. J Rheumatol. 2017 Oct; 44(10):1551-1559.
Score: 0.137
-
2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Rheumatol. 2017 08; 69(8):1538-1551.
Score: 0.136
-
Toward Ensuring Health Equity: Readability and Cultural Equivalence of OMERACT Patient-reported Outcome Measures. J Rheumatol. 2015 Dec; 42(12):2448-59.
Score: 0.118
-
Updating the OMERACT filter: discrimination and feasibility. J Rheumatol. 2014 May; 41(5):1005-10.
Score: 0.109
-
Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validity. J Rheumatol. 2014 May; 41(5):1000-4.
Score: 0.109
-
Updating the OMERACT filter: core areas as a basis for defining core outcome sets. J Rheumatol. 2014 May; 41(5):994-9.
Score: 0.108
-
How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0. J Rheumatol. 2014 May; 41(5):1025-30.
Score: 0.108
-
Updating the OMERACT filter: implications for imaging and soluble biomarkers. J Rheumatol. 2014 May; 41(5):1016-24.
Score: 0.108
-
Including health equity considerations in development of instruments for rheumatology research: an introduction to a novel OMERACT paradigm. J Rheumatol. 2014 Jan; 41(1):150-2.
Score: 0.105
-
Classification criteria in rheumatic diseases: a review of methodologic properties. Arthritis Rheum. 2007 Oct 15; 57(7):1119-33.
Score: 0.070
-
2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. J Arthroplasty. 2017 09; 32(9):2628-2638.
Score: 0.034
-
Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J Clin Epidemiol. 2014 Jul; 67(7):745-53.
Score: 0.027